AIM ImmunoTech Inc.
AIM NYSE· Biological Products, (No Diagnostic Substances)
Last close · Oct 26, 2026
$0.16
KIRA · Stoqly’s AI analyst, in plain words
- AIM ImmunoTech Inc. had $0.1M of revenue in fiscal 2025, down 48.2% on the year before. Over five years, revenue changed −11.6% a year on average.
- Its operating margin was −13,254.5%, down 1,624.0 pts: of every 100 in sales, about −13,255 is left after running the business.
- AIM ImmunoTech Inc. lost $14.0M in fiscal 2025.
- AIM ImmunoTech Inc. owes $1.4M more than it holds in cash.
Market cap
$2.8M
P/E
—
Revenue
$0.1M
Net income
−$14.0M
Free cash flow
—
Operating margin
−13,254.5%
AIM ImmunoTech Inc. in 30 seconds · fiscal 2025
Are sales growing?
−48.2%
No. Sales fell 48.2% last year.
Does it make a profit?
−15,861.4%
No. It lost money last year.
How healthy are the accounts?
2 / 8
Weak. It passes 2 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What AIM ImmunoTech Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 27, 2026
- Legal name
- AIM ImmunoTech Inc.
- CIK
- 0000946644
AIM ImmunoTech Inc. · AIM
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.1M | $0.1M | $0.2M | $0.2M | $0.1M |
| Revenue growth | −17.2% | 4.4% | 43.3% | −15.8% | −48.2% |
| Operating margin | −13,954.1% | −14,129.8% | −15,800.0% | −11,630.6% | −13,254.5% |
| Net income | −$19.1M | −$19.4M | −$29.0M | −$17.3M | −$14.0M |
| Net margin | −14,168.1% | −13,790.8% | −14,337.6% | −10,188.2% | −15,861.4% |
| Diluted EPS | −$0.40 | −$0.40 | −$0.60 | −$30.92 | −$8.62 |
| Cash | |||||
| Cash from operations | −$14.0M | −$16.1M | −$21.3M | −$14.9M | −$11.0M |
| Capital expenditure | $0.0M | $0.1M | — | $0.0M | — |
| Free cash flow | −$14.0M | −$16.2M | — | −$14.9M | — |
| FCF margin | −10,374.8% | −11,485.1% | — | −8,768.2% | — |
| Share count change | 48.7% | 1.5% | 1.1% | −98.8% | 188.9% |
| Debt and strength | |||||
| Cash and short-term investments | $48.3M | $34.2M | $13.1M | $4.0M | $3.0M |
| Debt incl. finance leases | — | — | — | $2.8M | $4.5M |
| Shareholders' equity | $56.9M | $38.5M | $10.2M | −$1.3M | −$9.8M |
| Current ratio | 74.6x | 26.7x | 1.7x | 0.4x | 0.5x |
| Interest coverage | −281.2x | — | — | −33.8x | −14.4x |
| Returns and quality | |||||
| Return on equity | −32.4% | −40.8% | −118.9% | −388.7% | — |
| Return on tangible equity | −34.8% | −53.2% | −365.6% | — | — |
| Piotroski F-score | 2 | 2 | 2 | 3 | 2 |
| Altman Z'' | 55.9 | −8.3 | −76.8 | −181.3 | −266.1 |
Insiders bought, 12 months
$0.0M
1 insider
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
AIM ImmunoTech Inc. · AIM
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.16 a share, the company is worth $2.8M.
Source: SEC EDGAR XBRL filings (CIK 0000946644). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.